Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

An assessment of the impact of herb-drug combinations used by cancer patients.

Alsanad SM, Howard RL, Williamson EM.

BMC Complement Altern Med. 2016 Oct 18;16(1):393.

2.

Hypericin in the Light and in the Dark: Two Sides of the Same Coin.

Jendželovská Z, Jendželovský R, Kuchárová B, Fedoročko P.

Front Plant Sci. 2016 May 6;7:560. doi: 10.3389/fpls.2016.00560. eCollection 2016. Review.

3.

A Review of Integrative Medicine in Gynaecological Oncology.

Kalder M, Müller T, Fischer D, Müller A, Bader W, Beckmann MW, Brucker C, Hack CC, Hanf V, Hasenburg A, Hein A, Jud S, Kiechle M, Klein E, Paepke D, Rotmann A, Schütz F, Dobos G, Voiß P, Kümmel S.

Geburtshilfe Frauenheilkd. 2016 Feb;76(2):150-155. Review.

4.

Interpreting Research on Dietary Supplements and Cancer - What is the Take Home Message?

Miller PE, Andrzejewski L, Chyan W, Snyder DC.

Oncol Nutr Connect. 2009 Spring;17(3):3-9. No abstract available.

5.

Role of pregnane X receptor in chemotherapeutic treatment.

Zhuo W, Hu L, Lv J, Wang H, Zhou H, Fan L.

Cancer Chemother Pharmacol. 2014 Aug;74(2):217-27. doi: 10.1007/s00280-014-2494-9. Epub 2014 Jun 3. Review.

6.

Underestimating the toxicological challenges associated with the use of herbal medicinal products in developing countries.

Neergheen-Bhujun VS.

Biomed Res Int. 2013;2013:804086. doi: 10.1155/2013/804086. Epub 2013 Sep 19. Review.

7.
8.

Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response.

Zhang W, Zheng Y, Hou L.

Curr Genet Med Rep. 2013 Sep 1;1(3):143-149.

9.

Therapeutic applications of herbal medicines for cancer patients.

Yin SY, Wei WC, Jian FY, Yang NS.

Evid Based Complement Alternat Med. 2013;2013:302426. doi: 10.1155/2013/302426. Epub 2013 Jul 11.

10.

Adverse events associated with complementary and alternative medicine use in ovarian cancer patients.

Sweet ES, Standish LJ, Goff BA, Andersen MR.

Integr Cancer Ther. 2013 Nov;12(6):508-16. doi: 10.1177/1534735413485815. Epub 2013 Apr 26. Review.

11.

Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Swami U, Goel S, Mani S.

Curr Drug Targets. 2013 Jun;14(7):777-97. Review.

12.

Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs.

van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG.

Br J Cancer. 2013 Mar 19;108(5):1071-8. doi: 10.1038/bjc.2013.48. Epub 2013 Feb 14.

13.

Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.

Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D.

Biochem Pharmacol. 2012 Apr 15;83(8):1112-26. doi: 10.1016/j.bcp.2012.01.030. Epub 2012 Feb 4. Review.

14.

Complementary and alternative medicine use in oncology: a questionnaire survey of patients and health care professionals.

Chang KH, Brodie R, Choong MA, Sweeney KJ, Kerin MJ.

BMC Cancer. 2011 May 24;11:196. doi: 10.1186/1471-2407-11-196.

15.

Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models.

Xie G, Sun Y, Nie T, Mackenzie GG, Huang L, Kopelovich L, Komninou D, Rigas B.

J Pharmacol Exp Ther. 2011 Jun;337(3):876-86. doi: 10.1124/jpet.111.180224. Epub 2011 Mar 21.

16.

Optimizing chemotherapy: concomitant medication lists.

Hanigan MH, Dela Cruz BL, Shord SS, Medina PJ, Fazili J, Thompson DM.

Clin Pharmacol Ther. 2011 Jan;89(1):114-9. doi: 10.1038/clpt.2010.253. Epub 2010 Dec 1.

17.

Drug interactions in childhood cancer.

Haidar C, Jeha S.

Lancet Oncol. 2011 Jan;12(1):92-9. doi: 10.1016/S1470-2045(10)70105-4. Epub 2010 Sep 22. Review.

18.

Effects of methimazole on the elimination of irinotecan.

van der Bol JM, Visser TJ, Loos WJ, de Jong FA, Wiemer EA, van Aken MO, Planting AS, Schellens JH, Verweij J, Mathijssen RH.

Cancer Chemother Pharmacol. 2011 Jan;67(1):231-6. doi: 10.1007/s00280-010-1414-x. Epub 2010 Aug 1.

19.

Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.

Borrelli F, Izzo AA.

AAPS J. 2009 Dec;11(4):710-27. doi: 10.1208/s12248-009-9146-8. Epub 2009 Oct 27. Review.

20.

Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.

Biswas A, Mani S, Redinbo MR, Krasowski MD, Li H, Ekins S.

Pharm Res. 2009 Aug;26(8):1807-15. doi: 10.1007/s11095-009-9901-7. Epub 2009 May 5. Review.

Supplemental Content

Support Center